in this open , controlled , randomized multi-clinic trial , monotherapy with imipenem/cilastatin was compared to amikacin plus piperacillin as empiric antibacterial therapy in 210 neutropenic cancer patients .
C0002499
amikacin
C0279516
antibacterial